Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 28NSCLC 4Brain Neoplasms 4Lung Neoplasms 3Pancreatic Neoplasms 2EGF-R Positive Non-Small Cell Lung Cancer 2Adenocarcinoma 2Squamous Cell Carcinoma of Lung 1Plasma EGFR Mutation-positive Lung Cancer 1Non-squamous Non-small Cell Lung Cancer 1Non-Small-Cell Lung 1Neoplasms, Second Primary 1Nasopharyngeal Carcinoma 1Esophageal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Adenocarcinoma of Lung 1

Interventions

Gefitinib 9Pemetrexed 7Carboplatin 5Gemcitabine 4Cisplatin 4apatinib 3Docetaxel 3aflutinib 2Neoadjuvant Therapy 2Erlotinib Hydrochloride 2Bevacizumab 2tislelizumab 1pembrolizumab 1motesanib diphosphate 1lometrexol 1icotinib 1endostar protein 1camrelizumab 1Watchful Waiting 1Thymalfasin 1Radiomics 1Platinum Compounds 1Paclitaxel 1Lymph Node Excision 1Indium 1Immune Checkpoint Inhibitors 1High-Throughput Nucleotide Sequencing 1Folic Acid 1Exome 1Exercise 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Adenocarcinoma of Lung × icotinib × Clear all
NCT02737774 2020-07-01

Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation

Henan Cancer Hospital

Phase 2 Unknown
60 enrolled
Thoracic

Adenocarcinoma of Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡